[A strategy for increasing the efficiency of psychopharmacological treatment of hyperkinetic behavior disorder with pantogam]. / Strategiia povysheniia éffektivnosti psikhofarmakologicheskogo lecheniia giperkineticheskogo rasstroistva povedeniia s primeneniem pantogama.

AIM: To assess short-term efficiency of hopantenic acid (pantogam) in the treatment of children with hyperkinetic behavior disorder, in whom the previous treatment with atomoxetine was not efficient. MATERIAL AND METHODS: Twenty-four children (16 boys and 8 girls), aged 6-11 years, diagnosed with hyperkinetic behavior disorder (ICD-10 item F90.1) were enrolled in this open non-randomized study. RESULTS AND CONCLUSION: A short-term positive therapeutic dynamics was observed when introducing hopantenic acid (pantogam) augmentation strategy to existing atomoxetine therapy. Qualitative improvements in children's state were found not only in the ability to control symptoms but also in their social functioning levels and quality of life. The proposed therapeutic strategy can help to improve treatment outcomes for children with certain clinical forms of hyperkinetic behavior disorder.

[Pantogam augmentation in hyperkinetic behavior disorder treatment]. / Povyshenie effektivnosti lecheniya giperkineticheskikh rasstroistv s primeneniem pantogama.

A clinical case of a child with hyperkinetic conduct disorder is presented, with symptoms of hyperkinetic disorder itself closely intertwining with symptoms of conduct disorder. The qualitative changes in the child's condition are noted, including not only achieved control over the symptoms, but also improved social functioning level, achieved by means of Pantogam (neuroprotective drug) addition to atomoxetine therapy. The proposed strategy can contribute to improvement of treatment results for children with certain clinical types of hyperkinetic conduct disorder.

[The influence of premorbid functioning on the efficacy of psychosocial therapy in adolescents with schizophrenia spectrum disorders]. / Vliianie urovnia premorbidnogo funktsionirovaniia na éffektivnost' gruppovoĭ psikhosotsial'noĭ terapii u podrostkov s rasstroĭstvami shizofrenicheskogo spektra.

AIM: To explore an effect of premorbid functioning level on the efficacy of psychosocial therapy in adolescents with schizophrenia spectrum disorders in order to determine a differential approach to its performance. MATERIAL AND METHODS: A study included 53 adolescents with schizophrenia spectrum disorders at the early stage of remission achievement (PANSS scores <65). An impact of premorbid functioning was assessed with the DD-CGAS and the efficacy of psychosocial therapy with CGAS and PedsQL at baseline and after 3, 6 and 12 months. RESULTS AND CONCLUSION: We described the most relevant differences in characteristics of treatment effect (dc) between three groups with different levels of premorbid functioning. To increase the efficacy of psychosocial interventions, we suggest a differential approach of psychosocial therapy in each group.

[Influence of psychosocial therapy on funcioning of adolescents with schizophrenia spectrum disorders (a pilot study)].

Authors studied the influence of psychosocial group therapy (PST) in adolescents with schizophrenia spectrum disorders on the dynamics of their social functioning based on the PedsQL questionnaire and the CGAS children general functioning assessment scale. There was a statistically significant improvement of basic indicators of adolescent social functioning in the main group after the PST cycle (3 months), while no proven between main and comparison groups difference was detected in the therapeutic dynamics, according to the PANSS scale, that confirmed the effectiveness of PST inclusion into psychosocial therapy and rehabilitation of adolescents with schizophrenia spectrum disorders. Three groups of adolescents were defined within the main group; trends towards changes in social functioning, depending on the type of disease course, were noted.

[Family burden as a target of psychosocial rehabilitation of children and adolescents with mental disorders].

Correlations between indices of family burden and changes in children's social functioning during psychosocial group therapy with parents of children and adolescents with schizophrenia spectrum disorders have been studied. A sample included 140 children and their mothers. Family burden was considered as a separate "target" of psychosocial rehabilitation of children and adolescents with mental disorders. The authors recommend to use this dynamic characteristic of family burden in the development of individualized treatment/prevention programs (modules) and corresponding measures with assessment of their effectiveness in the implementation of psychosocial support to the family. A significant positive effect of this psychosocial group therapy was confirmed by a set of specific scales and questionnaires.

[Sertraline in child and adolescent psychiatry]. / Primenenie sertralina v detskoi i podrostkovoi psikhiatrii.

The aim of the study was to research the efficiency of sertraline (zoloft) in depressions, anxious states and obsessive-compulsive disorders. Diagnosis of the mental disorders was carried out according to ICD-10. 72 children (59 boys, 13 girls) aged 6-18 years were treated. There were 32 inpatients and 40 outpatients. Therapy with sertraline was performed during 8 weeks with a gradual increase (titration) and individual selection of the dose from 12.5 to 100 mg/day. During the therapy clinical observation was combined with the patients' examination using Hamilton Depression Scale and Hamilton Anxiety Scale (HAM-D and HAM-A), and a Clinical Global Impression Scale (CGI). It was established that sertraline was very effective and safe drug in children (it has no influence on cognitive functions, has neither myorelaxing or sedative effects). Activity of this drug is characterized by quick manifestation of thymoanaleptic and anxiolytic effects. It mild depressive states 50 mg/day is a significant dose; in more severe depressions and obsessive-compulsive disorders the dose in juveniles was to 100 mg, the duration of the therapy was more than 2 months.